NO20064576L - Pyrimidin-derivater for behandling av avvikende celle vekst - Google Patents

Pyrimidin-derivater for behandling av avvikende celle vekst

Info

Publication number
NO20064576L
NO20064576L NO20064576A NO20064576A NO20064576L NO 20064576 L NO20064576 L NO 20064576L NO 20064576 A NO20064576 A NO 20064576A NO 20064576 A NO20064576 A NO 20064576A NO 20064576 L NO20064576 L NO 20064576L
Authority
NO
Norway
Prior art keywords
cell growth
treatment
aberrant cell
pyrimidine derivatives
compounds
Prior art date
Application number
NO20064576A
Other languages
English (en)
Norwegian (no)
Inventor
Michael Joseph Luzzio
John Charles Kath
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20064576(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20064576L publication Critical patent/NO20064576L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20064576A 2004-05-14 2006-10-09 Pyrimidin-derivater for behandling av avvikende celle vekst NO20064576L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57131204P 2004-05-14 2004-05-14
PCT/IB2005/001201 WO2005111023A1 (en) 2004-05-14 2005-05-02 Pyrimidine derivatives for the treatment of abnormal cell growth

Publications (1)

Publication Number Publication Date
NO20064576L true NO20064576L (no) 2006-11-07

Family

ID=34966230

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064576A NO20064576L (no) 2004-05-14 2006-10-09 Pyrimidin-derivater for behandling av avvikende celle vekst

Country Status (27)

Country Link
EP (1) EP1751143A1 (es)
JP (1) JP4099212B2 (es)
KR (1) KR100886990B1 (es)
CN (2) CN102127058A (es)
AP (1) AP2241A (es)
AR (1) AR049097A1 (es)
AU (2) AU2005243397A1 (es)
BR (1) BRPI0511138A (es)
CA (1) CA2566707A1 (es)
CR (1) CR8749A (es)
EA (1) EA200601796A1 (es)
EC (1) ECSP066997A (es)
GE (1) GEP20104875B (es)
GT (1) GT200500113A (es)
IL (1) IL178828A0 (es)
MA (1) MA28583B1 (es)
MX (1) MXPA06011890A (es)
NL (2) NL1029045C2 (es)
NO (1) NO20064576L (es)
NZ (1) NZ550448A (es)
PA (1) PA8632601A1 (es)
PE (1) PE20060240A1 (es)
TN (1) TNSN06370A1 (es)
TW (1) TWI303635B (es)
UY (1) UY28894A1 (es)
WO (1) WO2005111023A1 (es)
ZA (1) ZA200608394B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4812763B2 (ja) * 2004-05-18 2011-11-09 ライジェル ファーマシューティカルズ, インコーポレイテッド シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
EP1966207A2 (en) * 2005-12-21 2008-09-10 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
DK2146779T3 (en) * 2007-04-18 2016-11-28 Pfizer Prod Inc Sulfonylamid derivatives to treat abnormal cell growth.
CN101903357A (zh) * 2007-07-17 2010-12-01 里格尔药品股份有限公司 作为pkc抑制剂的环状胺取代的嘧啶二胺
US8461147B2 (en) * 2007-12-03 2013-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
JP2011523646A (ja) * 2008-05-21 2011-08-18 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのリン誘導体
US8410126B2 (en) * 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
US8729265B2 (en) 2009-08-14 2014-05-20 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
WO2014174745A1 (ja) * 2013-04-26 2014-10-30 国立大学法人京都大学 Eg5阻害剤
CN109608444B (zh) * 2018-11-27 2022-02-11 中国药科大学 含异吲哚啉酮的erk抑制剂及其制备方法与用途
CN111732548B (zh) * 2020-06-11 2022-06-17 浙江大学 N2-氨甲酰芳环-2-氨基嘧啶类衍生物及其医药用途
WO2024140671A1 (zh) * 2022-12-29 2024-07-04 南京昕瑞再生医药科技有限公司 一种稠三环类衍生物、包含其的药物组合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
SI1625121T1 (sl) * 2002-12-20 2010-04-30 Pfizer Prod Inc Derivati pirimidina za zdravljenje abnormalne rasti celic
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
NZ550448A (en) 2010-11-26
UY28894A1 (es) 2005-12-30
NL1029045C2 (nl) 2006-06-02
AP2006003790A0 (en) 2006-10-31
TNSN06370A1 (fr) 2008-02-22
IL178828A0 (en) 2007-03-08
ECSP066997A (es) 2007-02-28
ZA200608394B (en) 2008-05-28
PE20060240A1 (es) 2006-04-01
MA28583B1 (fr) 2007-05-02
AU2005243397A1 (en) 2005-11-24
CA2566707A1 (en) 2005-11-24
NL1029045A1 (nl) 2005-11-15
GEP20104875B (en) 2010-01-11
GT200500113A (es) 2006-01-10
KR100886990B1 (ko) 2009-03-04
CR8749A (es) 2006-12-05
BRPI0511138A (pt) 2007-11-27
EP1751143A1 (en) 2007-02-14
CN1953974A (zh) 2007-04-25
CN102127058A (zh) 2011-07-20
MXPA06011890A (es) 2006-12-14
NL1031845A1 (nl) 2006-07-31
AR049097A1 (es) 2006-06-28
AU2009238255A1 (en) 2009-12-03
JP4099212B2 (ja) 2008-06-11
KR20070012477A (ko) 2007-01-25
NL1031845C2 (nl) 2006-11-23
WO2005111023A1 (en) 2005-11-24
PA8632601A1 (es) 2006-06-02
JP2007537234A (ja) 2007-12-20
AP2241A (en) 2011-06-01
EA200601796A1 (ru) 2007-04-27
TWI303635B (en) 2008-12-01
TW200539871A (en) 2005-12-16

Similar Documents

Publication Publication Date Title
NO20054852L (no) GFAT inhibitorer
NO20082338L (no) Pyrimidinderivater for behandling av avvikende cellevekst
NO20061432L (no) N3 alkylerte benzimidazolederivater som MEK-inhibitorer
NO20092033L (no) Nye forbindelser
NO20083114L (no) Polysykliske indazolderivater som er ERK-inhibitorer
NO20080789L (no) 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid
NO20055421L (no) Kinolinderivater som fosfodiestrase-inhibitorer
NO20050921L (no) Nye fysiologisk aktive substanser
NO20050828L (no) lndol-3-svovelderivater
NO20062130L (no) 4-(pyrazol-3-ylamino)pyrimidinderivater for anvendelse i behandling av kreft
NO20061793L (no) 1,4-disubstituerte isoquinilonderlvater som RAF-kinaseinhibitorer nyttige for behandling av proliferative sykdommer
NO20080728L (no) Nye 1,4-benzotiazepin-1,1-dioksidderivater som har forbedrede egenskaper, fremgangsmate for fremstilling derav, medikamenter inneholdende nevnte forbindelsene og anvendelse derav
BRPI0511512A (pt) derivados pirrolpirimidina úteis no tratamento do cáncer
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
NO20051303L (no) Nye benzoimidazolderivater nyttige som antiproliferative midler
TNSN06074A1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
NO20076196L (no) Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander
NO20063928L (no) Substituerte kinolinforbindelser
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20065456L (no) Substituerte morfolinforbindelser for behandling av sykdommer i sentralnervesystemet
NO20055688L (no) Organiske forbindelser
NO20082077L (no) Spirosykliske quinazolinderivater som PDE7-inhibitorer
NO20063821L (no) Kinolinderivater for anvendelse som mykobakterielle inhibitorer
CY1111327T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος
NO20070089L (no) DPP-IV inhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application